|
|
|
|
|
Actonel: profile and news
Oscient Pharmaceuticals Reports Financial Results for Fourth ... 07 Mar 2006 Sunitinib Malate (Sutent) Provides Long-Lasting Responses in ... Feb 2, 2006 Novartis loses EMRs for the cancer drug Feb 21, 2006 Oscient Pharmaceuticals to Present at Fifth Annual JMP Securities ... Mar 2, 2006 Generics Hail Novartis Loss Feb 10, 2006 New Hope for Stomach Cancer Mar 1, 2006 Subcutaneous Amifostine Feasible During Radiotherapy for Head and ... Mar 1, 2006 Novartis denied patent for cancer drug Feb 9, 2006 MDCT Appearance of Gastrointestinal Stromal Tumors After Therapy ... Feb 14, 2006 Cell Genesys Reports Fourth Quarter and Full Year 2005 Results Feb 21, 2006 Antigenics Reports Fourth Quarter and Year-End 2005 Financial ... Feb 23, 2006 New Hope For Stomach Cancer Feb 24, 2006 NOVARTIS PATENT APPLICATION FOR CANCER DRUG FOUND INSUFFICIENT IN ... Feb 16, 2006 Test Now Available to Detect Resistance to Gleevec® in Chronic ... Feb 23, 2006 New drug fights GI tumors Feb 22, 2006 Webcast Alert: Oscient Pharmaceuticals Announces Date for Release ... Feb 22, 2006 Senetek Licenses Invicorp(R) Erectile Dysfunction Treatment to ... Feb 21, 2006 Oscient Pharmaceuticals and Pfizer Enter Agreement for FACTIVE ... Feb 7, 2006 Senetek Licenses Invicorp(R) Erectile Dysfunction Treatment to ... Feb 21, 2006 Oscient Pharmaceuticals and Pfizer Enter Agreement for FACTIVE ... Feb 7, 2006 Senetek Licenses Invicorp Erectile Dysfunction Treatment to ... Feb 21, 2006 Oscient Pharmaceuticals y Pfizer celebran acuerdo por las... Feb 7, 2006 UPDATE 1-Roche to discontinue US sales of AIDS drug Feb 6, 2006 Patent remedy for India’s health Feb 9, 2006 Novartis denied patent for cancer drug, Gleevec Feb 9, 2006 Roche to Focus Resources on Availability of Invirase, Now ... Feb 6, 2006 Genzyme Launches Key Test to Monitor Gleevec(R) Resistance Feb 9, 2006 Pfizer acquires rights to Oscient antibiotic in Mexico Feb 9, 2006 Power3's Invited Review on Biomarkers and Test for ALS ... Feb 14, 2006 New oral drug could make Thalassemia treatment less painful for ... Feb 8, 2006 Genzyme launches test to monitor Gleevec resistance Feb 13, 2006 Pharmaceutical Companies Look to Biomarkers to Help in Increasing ... Feb 2, 2006 Other information Indication For the treatment of Paget's disease of the bone (osteitis deformans); Postmenopausal and glucocorticoid-induced osteoporosis Pharmacology Risedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism and is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Mechanism Of Action The action of Risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Risedronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass. Drug Category Antiresorptives; Bisphosphonates; Antihypocalcemic Agents; Brand Names/Synonyms Actonel; Pyridine N-Oxide; Pyridostigmine Bromide; Pyridostigmine Bromine; Risedronate; Risedronate Sodium; Risedronic Acid Dosage Forms TABLET Absorption Rapid absorption (~1 hr) after an oral dose, occurs throughout the upper gastrointestinal tract Interactions -->Interactions for Risedronate: No specific drug-drug interaction studies were performed. Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (Cytochrome P450). Calcium Supplements/Antacids Co-administration of ACTONEL and calcium, antacids, or oral medications containing divalent cations will interfere with the absorption of ACTONEL. Hormone Replacement Therapy One study of about 500 early postmenopausal women has been conducted to date in which treatment with ACTONEL (5 mg/day) plus estrogen replacement therapy was compared to estrogen replacement therapy alone. Exposure to study drugs was approximately 12 to 18 months and the primary endpoint was change in BMD. If considered appropriate, ACTONEL may be used concomitantly with hormone replacement therapy. Aspirin/Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Of over 5700 patients enrolled in the ACTONEL Phase 3 osteoporosis studies, aspirin use was reported by 31% of patients, 24% of whom were regular users (3 or more days per week). Forty-eight percent of patients reported NSAID use, 21% of whom were regular users. Among regular aspirin or NSAID users, the incidence of upper gastrointestinal adverse experiences in ACTONEL-treated patients (24.5%) was similar to that in placebo-treated patients (24.8%). H2 Blockers and Proton Pump Inhibitors (PPIs) Of over 5700 patients enrolled in the ACTONEL Phase 3 osteoporosis studies, 21% used H2 blockers and/or PPIs. Among these patients, the incidence of upper gastrointestinal adverse experiences in the ACTONEL-treated patients was similar to that in placebo-treated patients. Drug/Laboratory Test Interactions Bisphosphonates are known to interfere with the use of bone-imaging agents. Specific studies with ACTONEL have not been performed. Chemical IUPAC Name (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonicacid Chemical Formula C7H11NO7P2 Half Life 1.5 hours Drug Type Approved Drug # Accession No APRD00410 CAS Registry Number 105462-24-6 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |